Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chronic neural activity recorded within breast tumors
Scientific Reports Open Access 09 September 2020
-
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
Nature Communications Open Access 04 October 2018
-
Role of the nervous system in cancer metastasis
Journal of Experimental & Clinical Cancer Research Open Access 15 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coghill, A. E., Newcomb, P. A. & Potter, J. D. Aspirin use, colorectal cancer survival, and loss to follow-up. JAMA 302, 2549 (2009).
Schuller, H. M. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1, 466–469 (2010).
Algazi, M., Plu-Bureau, G., Flahault, A., Dondon, M.-G. & Le, M. G. Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett. Drug Des. Discov. 3, 653–661 (2006).
Bangalore, S. et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324168 participants from randomised trials. Lancet Oncol. 12, 65–82 (2011).
Sloan, E. K. et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70, 7042–7052 (2010).
Palm, D. et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer 118, 2744–2749 (2006).
Powe, D. et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1, 628–638 (2010).
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visanathan, K. Beta blockers and breast cancer mortality: a population based study. J. Clin. Oncol. 29, 2635–2644 (2011).
Melham-Bertrandt, A. et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 29, 2645–2652 (2011).
Powe, D. G. et al. Alpha and beta adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res. Treat. doi: 10.1007/s10549-011-1371-z.
Acknowledgements
The authors would like to acknowledge support provided by the Fritz-Bender Foundation, Munich, Germany.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Powe, D., Entschladen, F. Using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8, 511–512 (2011). https://doi.org/10.1038/nrclinonc.2011.123
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.123
This article is cited by
-
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models
Cancer Chemotherapy and Pharmacology (2023)
-
Neurotransmitters: emerging targets in cancer
Oncogene (2020)
-
Chronic neural activity recorded within breast tumors
Scientific Reports (2020)
-
Role of the nervous system in cancer metastasis
Journal of Experimental & Clinical Cancer Research (2018)
-
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
Nature Communications (2018)
